JAK/TYK2

      RT @drpnash: Tofacitinib for the Treatment of Adult Patients with Ankylosing Spondylitis: Primary Analysis of a Phase 3,

      Peter Nash drpnash

      4 years 11 months ago
      Tofacitinib for the Treatment of Adult Patients with Ankylosing Spondylitis: Primary Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study https://t.co/F86K1Lqou7 #tofacitinib #AS Tofa works in AS , zoster no VTE seen NNH 20(per SAE) NNT 2.5(per ASAS40)
      RT @ACRheum: The #ACR20 Great Debate will feature two experts discussing whether #JAK inhibitors should be used before b

      American College of Rheumatology ACRheum

      4 years 11 months ago
      The #ACR20 Great Debate will feature two experts discussing whether #JAK inhibitors should be used before biologics if methotrexate fails. The session runs Friday, Nov. 6., from 10:00 to 11:00 AM ET. Learn more → https://t.co/I8zTGn0Q06
      Xeljanz4.jpg
      Spondyloarthritis at ACR Convergence 2020
      4 years 11 months ago
      There are some really interesting poster and abstract presentations on spondyloarthritis at the ACR Convergence 2020. I’ll be covering these topics, and discussing select individual posters and abstracts during this meeting.  Here is a flavour of my read through the topics that are being covered during the meeting.  
      Axial Involvement in Psoriatic Arthritis: Dr. Eric Ruderman Perspective
      4 years 11 months ago

      Dr. Eric Ruderman, Chicago, IL., provides his perspective on ACR 2020 coverage of axial involvement in Psoriatic Arthritis. During his remarks, he discusses ACR abstracts #0344, #1372, #2025 and #0505. 

      Catch up on Conference Podcasts

      ×